N-[(1S,4R,5R,7S)-5-(3-isopropoxyphenyl)-4-methyl-2-azabicyclo[3.3.1]non-7-yl]-2-methyl-2-phenylpropanamide | 911422-99-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-[(1S,4R,5R,7S)-5-(3-isopropoxyphenyl)-4-methyl-2-azabicyclo[3.3.1]non-7-yl]-2-methyl-2-phenylpropanamide
• 英文别名: 2-methyl-N-[(1S,4R,5S,7S)-4-methyl-5-(3-propan-2-yloxyphenyl)-2-azabicyclo[3.3.1]nonan-7-yl]-2-phenylpropanamide
• CAS: 911422-99-6
• 化学式: C₂₈H₃₈N₂O₂
• 分子量: 434.622
• InChiKey: QFNUQXRIJKERFK-UFXRUVHKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-[(1S,4R,5R,7S)-5-(3-isopropoxyphenyl)-4-methyl-2-azabicyclo[3.3.1]non-7-yl]-2-methyl-2-phenylpropanamide 在 三溴化硼 、 四丁基碘化铵 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 74.5h， 生成 (+)-N-[(1S,4R,5R,7S)-5-(3-hydroxyphenyl)-4-methyl-2-(2-phenoxyethyl)-2-azabicyclo[3.3.1]non-7-yl]-2-methyl-2-phenylpropanamide
  参考文献：
  名称：

  Highly Potent and Selective Phenylmorphan-Based Inverse Agonists of the Opioid δ Receptor

  摘要：

  We recently reported the discovery of (+)-5-( 3-hydroxyphenyl)-4-methyl-2-( 3-phenylpropyl)-2-azabicyclo-[ 3.3.1] non-7-yl-( 1-phenyl-1-cyclopentane) carboxamide [(+)-KF4, (+)-5] as a novel chemotype possessing potent antagonist activity at the delta opioid receptor. Additional SAR studies involving changes to both the 2-amino and 7-amido N-substituents using this same (+)- morphan scaffold have revealed compounds with improved potency and selectivity for the delta opioid receptor. The highly potent and selective 2,2-dimethylphenylacetamide analogue (+)- N-[( 1S, 4R, 5R, 7S)-5-( 3-hydroxyphenyl)-4-methyl- 2-(3-phenylpropyl)2- azabicyclo[ 3.3.1] non-7-yl]-2-methyl-2-phenylpropanamide ( 13d, delmorphan-A) showed picomolar inhibitory potency ( K-e = 0.1 nM) in the [ S-35] GTP gamma S functional assay with delta opioid receptor selectivity ratios of 103- and 132- fold versus the mu and kappa opioid receptors, respectively. The compounds showed no agonist activity at any of the three opioid receptors; however, measurements of delta inverse agonist activity within this series illustrated a broad range of negative efficacy and IC50 values 650-fold more potent than the prototypical delta opioid receptor inverse agonist ICI 174 864 ( 22).

  DOI：

  10.1021/jm060459p
• 作为产物：
  描述：

  alpha,alpha-二甲基苯乙酸 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 三氟乙酸 为溶剂， 反应 5.5h， 生成 N-[(1S,4R,5R,7S)-5-(3-isopropoxyphenyl)-4-methyl-2-azabicyclo[3.3.1]non-7-yl]-2-methyl-2-phenylpropanamide
  参考文献：
  名称：

  Highly Potent and Selective Phenylmorphan-Based Inverse Agonists of the Opioid δ Receptor

  摘要：

  We recently reported the discovery of (+)-5-( 3-hydroxyphenyl)-4-methyl-2-( 3-phenylpropyl)-2-azabicyclo-[ 3.3.1] non-7-yl-( 1-phenyl-1-cyclopentane) carboxamide [(+)-KF4, (+)-5] as a novel chemotype possessing potent antagonist activity at the delta opioid receptor. Additional SAR studies involving changes to both the 2-amino and 7-amido N-substituents using this same (+)- morphan scaffold have revealed compounds with improved potency and selectivity for the delta opioid receptor. The highly potent and selective 2,2-dimethylphenylacetamide analogue (+)- N-[( 1S, 4R, 5R, 7S)-5-( 3-hydroxyphenyl)-4-methyl- 2-(3-phenylpropyl)2- azabicyclo[ 3.3.1] non-7-yl]-2-methyl-2-phenylpropanamide ( 13d, delmorphan-A) showed picomolar inhibitory potency ( K-e = 0.1 nM) in the [ S-35] GTP gamma S functional assay with delta opioid receptor selectivity ratios of 103- and 132- fold versus the mu and kappa opioid receptors, respectively. The compounds showed no agonist activity at any of the three opioid receptors; however, measurements of delta inverse agonist activity within this series illustrated a broad range of negative efficacy and IC50 values 650-fold more potent than the prototypical delta opioid receptor inverse agonist ICI 174 864 ( 22).

  DOI：

  10.1021/jm060459p

文献信息

• Highly Potent and Selective Phenylmorphan-Based Inverse Agonists of the Opioid δ Receptor
  作者：James B. Thomas、Li Zhang、Hernán A. Navarro、F. Ivy Carroll

  DOI：10.1021/jm060459p

  日期：2006.9.1

  We recently reported the discovery of (+)-5-( 3-hydroxyphenyl)-4-methyl-2-( 3-phenylpropyl)-2-azabicyclo-[ 3.3.1] non-7-yl-( 1-phenyl-1-cyclopentane) carboxamide [(+)-KF4, (+)-5] as a novel chemotype possessing potent antagonist activity at the delta opioid receptor. Additional SAR studies involving changes to both the 2-amino and 7-amido N-substituents using this same (+)- morphan scaffold have revealed compounds with improved potency and selectivity for the delta opioid receptor. The highly potent and selective 2,2-dimethylphenylacetamide analogue (+)- N-[( 1S, 4R, 5R, 7S)-5-( 3-hydroxyphenyl)-4-methyl- 2-(3-phenylpropyl)2- azabicyclo[ 3.3.1] non-7-yl]-2-methyl-2-phenylpropanamide ( 13d, delmorphan-A) showed picomolar inhibitory potency ( K-e = 0.1 nM) in the [ S-35] GTP gamma S functional assay with delta opioid receptor selectivity ratios of 103- and 132- fold versus the mu and kappa opioid receptors, respectively. The compounds showed no agonist activity at any of the three opioid receptors; however, measurements of delta inverse agonist activity within this series illustrated a broad range of negative efficacy and IC50 values 650-fold more potent than the prototypical delta opioid receptor inverse agonist ICI 174 864 ( 22).